<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1399">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 18, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753619</url>
  </required_header>
  <id_info>
    <org_study_id>PRO2021070003</org_study_id>
    <nct_id>NCT04753619</nct_id>
  </id_info>
  <brief_title>Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management</brief_title>
  <official_title>Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management (Randomized Controlled Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Baghdad</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Baghdad</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care&#xD;
      Measures in COVID-19 Management in a randomized controlled clinical trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol of therapy Niclosamaide Add on group&#xD;
&#xD;
        -  NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on&#xD;
           the 2nd day 1g x3 for 7 days. [ this means only in the first day 4 gm/d then on the&#xD;
           second day 3g/d in 3 divided doses for 7 days]&#xD;
&#xD;
        -  If the participant requires mechanical ventilation over the course of the study, NGT may&#xD;
           be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be&#xD;
           administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.&#xD;
&#xD;
      Control group The patients in this group will receive only standard care which will include&#xD;
      all or some of the following, according to the clinical condition of each patient:&#xD;
&#xD;
        -  Acetaminophen 500mg on need&#xD;
&#xD;
        -  Vitamin C 1000mg twice/ day&#xD;
&#xD;
        -  Zinc 75-125 mg/day&#xD;
&#xD;
        -  Vitamin D3 5000IU/day&#xD;
&#xD;
        -  Azithromycin 250mg/day for 5 days&#xD;
&#xD;
        -  Oxygen therapy/ C-Pap if needed&#xD;
&#xD;
        -  Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed&#xD;
&#xD;
        -  Mechanical ventilation, if needed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Anticipated">May 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Cure of the patient</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the percentage of cure of the patient and evaluated by normalization of clinical evaluation, laboratory investigations, and imaging.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>7 days</time_frame>
    <description>- to study the time to recovery ( stay days in hospital)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of Progressive patients</measure>
    <time_frame>7 days</time_frame>
    <description>- T assess percentage of progressive patients to more advanced disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mortality</measure>
    <time_frame>7 days</time_frame>
    <description>- To evaluate mortality rate among NCS add on group compared to controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>7 days</time_frame>
    <description>- To demonstrate side effects seen during the trial and will be assessed according clinical evaluation and the appropriate laboratory investigation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Covid-19</condition>
  <condition>SARS Pneumonia</condition>
  <arm_group>
    <arm_group_label>Niclosamide group: NCS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NCL + standard therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niclosamide Oral Tablet</intervention_name>
    <description>NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. [ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days]&#xD;
If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.</description>
    <arm_group_label>Niclosamide group: NCS group</arm_group_label>
    <other_name>Yomesan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with age above 18 years and of any gender.&#xD;
&#xD;
          2. Definite diagnosis of COVID-19 according to the WHO classification criteria ( 18).&#xD;
&#xD;
          3. Patients symptomatic for no more than three days for mild-moderate cases, no more than&#xD;
             two days after being severe cases, and no more than one day after being critical&#xD;
             cases.&#xD;
&#xD;
          4. Understands and agrees to comply with planned study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients refuse to enrol in the study&#xD;
&#xD;
          2. Patients with hypersensitivity or severe adverse effects to niclosamide&#xD;
&#xD;
          3. Renal impairment&#xD;
&#xD;
          4. Hepatic impairment&#xD;
&#xD;
          5. Pregnancy or a desire to become pregnant&#xD;
&#xD;
          6. Breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed S Abdulamir, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Medicine-Al-Nahrain University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faiq I. Gorial, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>College of Medicine-University of Baghdad</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal K abdulrrazaq, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>College of Medicine-University of Baghdad</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faiq I. Gorial, Professor</last_name>
    <phone>009647801730696</phone>
    <email>faiqig@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahmed S. Abdulamir</name>
      <address>
        <city>Baghdad</city>
        <state>Baghdada</state>
        <zip>00964</zip>
        <country>Iraq</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed S. Abdulamir, Professor</last_name>
      <phone>009747702677741</phone>
      <email>ahmsah73@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Faiq I. Gorial, Professor</last_name>
      <phone>009647801730696</phone>
      <email>faiqig@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iraq</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 13, 2021</last_update_submitted>
  <last_update_submitted_qc>February 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Baghdad</investigator_affiliation>
    <investigator_full_name>Faiq Gorial</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Niclosamide</keyword>
  <keyword>Covid-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niclosamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected IPD, all IPD that underlie results in a publication</ipd_description>
    <ipd_time_frame>6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Will be given by the principle investgator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

